PBM (Psyence Biomedical) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBM Psyence Biomedical Ltd PBM
14 GF Score
Price $5.40
! 4 Warning Signs
View Full Analysis

What is Psyence Biomedical Net Margin %?

Psyence Biomedical PBM +9.64% 14 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 949 Biotechnology companies, Psyence Biomedical ranks worse than 105373.97% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Psyence Biomedical's Net Income for the six months ended in Mar. 2026 was $-4.94 Mil. Psyence Biomedical's Revenue for the six months ended in Mar. 2026 was $0.00 Mil. Therefore, Psyence Biomedical's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Psyence Biomedical's Net Margin % or its related term are showing as below:


PBM's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -77.58
* Ranked among companies with meaningful Net Margin % only.

Psyence Biomedical  (NAS:PBM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Psyence Biomedical Net Margin % Related Terms

Psyence Biomedical Net Margin % Historical Data

* Premium members only.

The historical data trend for Psyence Biomedical's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psyence Biomedical Net Margin % Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PBM vs NRSN, PLUR, CALC: Net Margin % Comparison

For the Biotechnology subindustry, Psyence Biomedical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Net Margin % distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Net Margin % falls into.


PBM
14GF Score
Psyence Biomedical Ltd PBM
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psyence Biomedical Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Psyence Biomedical's Net Margin for the fiscal year that ended in Mar. 2026 is calculated as

Net Margin=Net Income (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-6.936/0
= %

Psyence Biomedical's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.943/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Psyence Biomedical (PBM) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Psyence Biomedical and its competitors. According to the industry distribution chart, Psyence Biomedical ranks #999999 out of 949 companies in the Biotechnology industry.
Is Psyence Biomedical's Net Margin % too high?
Psyence Biomedical's current Net Margin % is 0.00%. Based on the distribution chart, Psyence Biomedical ranks #999999 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Net Margin % compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #999999 out of 949 companies for Net Margin %. This places Psyence Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Psyence Biomedical and its competitors. Psyence Biomedical's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Psyence Biomedical Business Description

Address 121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score

Get the complete analysis for PBM

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.40
Price